These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 8683295)

  • 1. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia.
    Ballinger JR; Kee JW; Rauth AM
    J Nucl Med; 1996 Jun; 37(6):1023-31. PubMed ID: 8683295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors.
    Melo T; Duncan J; Ballinger JR; Rauth AM
    J Nucl Med; 2000 Jan; 41(1):169-76. PubMed ID: 10647620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics.
    Melo T; Hua HA; Ballinger JR; Rauth AM
    Biochem Pharmacol; 1997 Sep; 54(6):685-93. PubMed ID: 9310345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMS181321 accumulation in rodent and human cells: the role of P-glycoprotein.
    Cowan DS; Melo T; Park L; Ballinger JR; Rauth AM
    Br J Cancer Suppl; 1996 Jul; 27():S264-6. PubMed ID: 8763894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium.
    Kusuoka H; Hashimoto K; Fukuchi K; Nishimura T
    J Nucl Med; 1994 Aug; 35(8):1371-6. PubMed ID: 8046496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection.
    Zhang X; Melo T; Ballinger JR; Rauth AM
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):737-40. PubMed ID: 9845087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Siim BG; Laux WT; Rutland MD; Palmer BN; Wilson WR
    Cancer Res; 2000 Aug; 60(16):4582-8. PubMed ID: 10969810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
    Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
    J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia.
    Shi CQ; Sinusas AJ; Dione DP; Singer MJ; Young LH; Heller EN; Rinker BD; Wackers FJ; Zaret BL
    J Nucl Med; 1995 Jun; 36(6):1078-86. PubMed ID: 7769431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of technetium-99m-liposomes in tumor imaging.
    Goins B; Klipper R; Rudolph AS; Phillips WT
    J Nucl Med; 1994 Sep; 35(9):1491-8. PubMed ID: 8071699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
    Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
    J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel [99mTc[triple bond]N]2+ complex of metronidazole xanthate as a potential agent for targeting hypoxia.
    Mallia MB; Mathur A; Subramanian S; Banerjee S; Sarma HD; Venkatesh M
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3398-401. PubMed ID: 16044527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of technetium-99m glucarate: in vitro cell cultures and in vivo tumour models.
    Ballinger JR; Hsue V; Rauth AM
    Nucl Med Commun; 2003 May; 24(5):597-606. PubMed ID: 12717079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a second nitroimidazole redox centre on the accumulation of a hypoxia marker: synthesis and in vitro evaluation of 99mTc-labeled bisnitroimidazole propylene amine oxime complexes.
    Huang H; Zhou H; Li Z; Wang X; Chu T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):172-7. PubMed ID: 22153341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.
    Lewis JS; McCarthy DW; McCarthy TJ; Fujibayashi Y; Welch MJ
    J Nucl Med; 1999 Jan; 40(1):177-83. PubMed ID: 9935074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
    Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
    Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of hypoxic marker specificity and sensitivity.
    Iyer RV; Engelhardt EL; Stobbe CC; Schneider RF; Chapman JD
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):741-5. PubMed ID: 9845088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia.
    Ng CK; Sinusas AJ; Zaret BL; Soufer R
    Circulation; 1995 Sep; 92(5):1261-8. PubMed ID: 7648674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low flow and hypoxia on myocardial retention of technetium-99m BMS181321.
    Okada RD; Nguyen KN; Strauss HW; Johnson G
    Eur J Nucl Med; 1996 Apr; 23(4):443-7. PubMed ID: 8612666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marking hypoxia in rat prostate carcinomas with beta-D-[125I]azomycin galactopyranoside and.
    Iyer RV; Haynes PT; Schneider RF; Movsas B; Chapman JD
    J Nucl Med; 2001 Feb; 42(2):337-44. PubMed ID: 11216534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.